Summary
"The reported European and U.S. studies are far from surprising," said Dr. Amnon Gonenne, president and CEO of Mabcure Inc., a diagnostic company that has developed through its proprietary hybridoma technology a series of highly specific monoclonal antibodies (MAbs) against melanoma, ovarian carcinoma and prostate cancers. "Many doctors feel that the PSA test is over-subscribed in the U.S. compared to Europe. The notion that PSA is not useful for diagnosing prostate cancer or saving patients' Uves has been around for quite some time."
"Since the majority of prostate cancers are not life threatening, most men, depending on their age, are likely to die with the disease rather than from the disease," Dr. [Gonenne] said. "Therefore, the challenge of diagnosing prostate cancer in its early stage is not merely identifying the presence of cancer, but the ability to determine if the cancer is indolent and therefore of low risk, or aggressive and life threatening. Until prostate cancer-specific markers are identified, the diagnostic challenge of identifying men at risk will not be met.""At least one of our [MAbs] has been shown to have high specificity in that it does not react with normal prostate tissue, but only with diseased one," said Dr. Gonenne. "MabCure plans to expand its MAb repertoire as well as screen its anti-prostate cancer MAbs for their ability to detect early aggressive cancer in serum or urine."According to its website, MabCure's scientists have created proprietary MAbs using hybridomas, a hybrid cell that is a cross between antibody-producing immune system cells and a myeloma (blood or bone marrow cancer).\nSee the full content of this document
Extract
Conflicting Reports On Prostate Cancer
It seems every two or three years there are new reports and studies on prostate cancer and, far too often, the studies and reports offer conflicting views.
Last week, that practice continued with the announcement of two studies th...See the full content of this document
Sponsored links
